+ All Categories
Home > Documents > The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony...

The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony...

Date post: 29-Mar-2015
Category:
Upload: ian-lenn
View: 216 times
Download: 1 times
Share this document with a friend
Popular Tags:
63
the Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006
Transcript
Page 1: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

the Myelodysplastic Syndromes:

what they are, what they mean and what are we doing about it

Anthony Woods, MDSeptember 30, 2006

Page 2: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

outline

• what is myelodysplasia?• diagnosis & classification• treatment strategies• specialty clinics

Page 3: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

What is…?

“clonal disorder affecting hematopoietic maturation, characterized by ineffective hematopoiesis and bone marrow failure

with resultant cytopenias, often culminating in florid acute leukemia”

huh?

Page 4: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

historically

• reports of cytopenic disorders began appearing in the early 20th century

1942: “odo-leukemia” • odo = threshold (Chevalier et al)

1949: “preleukemic anemia” (Hamilton-Paterson)

1953: expanded definition to include all blood lines “clonal myeloid hemopathy”

(Block et al)

Page 5: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

historically

• other terms used over the last 50 years:– herald state of leukemia– refractory anemia– sideroachrestic anemia– idiopathic refractory sideroblastic anemia– pancytopenia with hyperplastic marrow– oligoblastic leukemia

Page 6: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

soapbox

no surprise that there is confusion and ignorance about this disorder:

historical coupling of MDS to acute myeloid leukemia

• there is a relationship• has hindered consideration of MDS as

a distinct entity– biased investigational and therapeutic

efforts towards the leukemia

Page 7: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

historically

• Paris, 1975: hemopoietic dysplasia– subsequently shortened to

myelodysplasia

• 1982: French-American-British classification scheme (FAB)

• 1999-2002: World Health Organization classification scheme

Page 8: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

What is myelodysplasia?

• disordered production of one or more cell lines

“dysplasia”

abnormal growth and differentiation of hematopoietic precursors

• abnormal appearance under the microscope

Page 9: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

normal blood

Page 10: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplastic features - blood

Page 11: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplastic features - blood

normal

Page 12: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplastic features - blood

Page 13: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

normal bone marrow

Page 14: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

normal bone marrow

Page 15: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplasia – bone marrow

Page 16: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplasia – bone marrow

Page 17: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplasia – bone marrow

Page 18: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

dysplasia – bone marrow

Page 19: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

what goes wrong with marrow cells?

• multistep process• sequence of successive DNA

mutations in an early blood cell precursor cell

• evolution of this cell into a “clone”– self-reproducing abnormal cell– growth advantage over normal marrow

cells

Page 20: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

what goes wrong with marrow cells?

complex multistep process:• DNA mutations in an early blood cell

precursor cell• emergence as an abnormal clone

– self-reproducing, abnormal cell– growth advantage over normal marrow

cells BUT at the same time incapable of producing normal blood cells

Page 21: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

what goes wrong with marrow cells?

expansion of the abnormal clone results in ineffective hematopoiesis– marrow looks full– no useful blood cell production actually

occurring– suppression and inhibition of normal

marrow growth

“weeds growing in the garden”Dr. R. Wells

Page 22: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

what goes wrong with marrow cells?

• worse, over time the clone becomes more and more unstable

• ~ 25% of persons with MDS develop acute myeloid leukemia

Page 23: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

what goes wrong with marrow cells?

C. Willman, ASH Education Program, 2000

MDS AML

Page 24: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

causes

• may follow exposures to bone marrow toxins– chemotherapy– radiation– organic compounds

• some follow inherited tendencies• Fanconi anemia, disorders of DNA repair

• > 80% have no identifiable exposure or cause

Page 25: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

in whom and how often

• can affect people of any age– including children

• more common in advancing age– North America: mid-late 60’s– China: 50

• 10000-15000 new diagnoses per year in USA– Canada 10% ?

Page 26: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

in whom and how often

MDS Foundation estimates that in people older than 70 there are

15 - 50 new diagnoses / 100,000 persons per year

extrapolating USA estimates, perhaps 3000 - 6000 Canadians have an MDS

diagnosis at any given time

Page 27: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

diagnosis

• requires suspicion• typically 2 settings where MDS

should be suspected:

1. signs or symptoms of a blood disorder

– fatigue, exercise intolerance, pale– serious or recurrent infections– inappropriate bleeding and bruising

Page 28: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

diagnosis

2. unexpected finding in blood suggesting MDS:

– low blood count of any kind• > 80% have anemia ± others• 30 – 45% have low platelets

– macrocytosis (large red cells)– high monocyte count– abnormal appearing blood cells

Page 29: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

diagnosis

required evaluation:• complete history and examination• complete blood counts and diff• iron, B12 and folate levels• bone marrow aspirate & biopsy

– chromosome analysis: “cytogenetics”

• serum erythropoietin levels– prior to transfusions

Page 30: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

diagnosis

• tests that are useful in some clinical circumstances

– HLA tissue typing (if BMT a consideration)

– HIV testing– other specific tests

• PNH• other HLA determinations

Page 31: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

diagnosis

• no perfect diagnostic test• no absolute diagnostic criteria

• combination of findings:– appearance of dysplasia in blood and

marrow– abnormal cytogenetic testing

Page 32: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

complications

related to low blood counts• fatigue, decreased exercise tolerance• serious, recurrent infection• bleeding

• the latter two are responsible for the majority of severe and life-threatening complications of MDS

Page 33: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

complications

• approximately 25% of patients undergo a transformation to acute myeloid leukemia

• arbitrary distinction of having 20% blast cells in bone marrow

• represents an increase in the aggressiveness of their MDS

• associated with a worse prognosis

Page 34: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

complications

suspected if:

• drop in baseline blood counts• higher blast cell numbers showing up

in blood• higher transfusion requirements• non-specific symptoms

– weight loss

Page 35: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

classification

2 classification systems still in use

• FAB System

• newer WHO classification

Page 36: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

FAB classification

• many clinicians still primarily use this system

• framework upon which newer classifications are built

• FAB grouping gives prognostic information: all tables from Steensma et al, May Clin Proc, 2006

Page 37: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

FAB classification

FAB median survival % progressing to class (months) acute leukemia

RA 37 11RARS 49 5RAEB 9 23

RAEB-t 6 48CMML 22 20

Page 38: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

WHO Classification

meant to refine the FAB system:• incorporated new information

– cytogenetics

• added subcategories for recognized specific sub-entities– 5q- syndrome

• also takes into account changes in AML diagnostic criteria– 20% vs 30%

Page 39: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

WHO Classification

Page 40: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

International Prognostic Scoring System

• need for a better system to predict prognosis in certain patient groups

• IPSS: a tool specifically designed for prognostic purposes

• arose out of a 1997 international workshop on MDS Risk Analysis

• analyzed factors in 816 patients

Page 41: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

IPSS calculation

Page 42: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• many potential therapies available to & tried in MDS patients

• most show some benefit

• most benefits are– small– only in a minority subset of patients

• hard to know who should receive them and what to expect

Page 43: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

transfusion and general supportive measures

• most persons with MDS require transfusion support at some time during their course

• most people do not tolerate hemoglobin < 80 g/L– at least 80 or for comfort/symptoms– CMV negative products in potential BMT

recipients

Page 44: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• platelet transfusion is individualized based on baseline counts and bleeding symptoms– alloimmunization to platelets– local blood bank guidelines

• adjunctive agents can be used– tranexamic acid

Page 45: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• management of iron overload– Dr. Wells

Page 46: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• prompt attention given to infectious symptoms

• primary care physicians should be aware of increased importance of infections in persons with MDS

• trials of growth factors with infections– inpatient setting– selected outpatients

Page 47: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

growth factors: erythropoietin and G-CSF

• rationale is to encourage hematopoiesis

• responses are variable

• expensive, not readily obtainable to everyone– 3rd party insurance– “sneak” past renal guidelines

Page 48: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy• EPO compounds (Eprex) have

generally shown response rates of 15-20%

• better responses seen in:– RCMD-RS– low EPO levels– lighter transfusion needs

• responses generally last 1-2 years• doses: 40-60,000 units SC weekly• newer compounds appear equally

effective– darbepoietin (Aranesp)

Page 49: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• response rates may increase up to twofold if recombinant granulocyte colony stimulating factor (G-CSF) is added

• generally done in a stepwise fashion• doses of 1 µcg/kg day typical starting

point

• similar difficulties in obtaining drug

Page 50: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

chemotherapy

• high-risk MDS patients with high blast counts or those who have transformed are candidates for treatment with traditional chemotherapy regimens

• similar to AML therapy

Page 51: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

epigenetic therapy

• DNA transcription (and normal cell growth and development) in MDS can be altered by factors not directly related to DNA sequences– chemical alterations of DNA itself– chemical changes in support proteins

• histones

Page 52: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• demethylation agents: allow transcription of key tumor suppressor genes

• histone deacetylation agents: alter binding of DNA to histones and increase “accessibility” of DNA to transcription factors

Page 53: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

5-azacytidine• methyltransferase inhibitor

• delays progression of MDS• improvements in blood counts in ~

20% patients• improvements in quality of life• neutropenia observed as side effect

(!)

Page 54: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

5-aza-2’-deoxycytabine (decitabine)• similar mechanism• less neutropenia & similar response

rates– perhaps substantially better in some

European studies

• availability and difficulties with awkward approved dosing schedules have been obstacles

Page 55: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

immune suppression• antithymocyte globulin, cyclosporine

– responses of 20-30% in trials– pts with relatively hypoplastic marrows

appear to be better candidates

immunomodulatory therapy• thalidomide and lenalidomide

Page 56: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

thalidomide has shown promise, but has an unfavorable toxicity profile in MDS

• have had > 33% drop-out rates in studies

Page 57: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

lenalidomide (Revlimid): exciting!• large improvements seen in

transfusion requirements– best in 5q- patients, but also in other

karyotypes– normalization of cytogenetics

• appears much less toxic– reversible neutropenia and

thrombocytopenia

• availability!

Page 58: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• vitamins: high-dose B complex• danazol: thrombocytopenia• monoclonal antibodies• splenectomy

all may have roles in individual patients

Page 59: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy

• stem cell transplantation– Dr. L. Savoie

• definite role in select patients– higher-risk disease– younger patients

Page 60: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

therapy: general algorithm

BMT transplant candidate:

•young

•good performance status

•high risk MDS

•suitable donor

YES consider BMT

NO

Low risk MDS:•clinical trials•growth factors•biological agents•immune therapy

High risk MDS:•clinical trials•leukemia-styletherapy•biological agents

Page 61: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

The Role of the Specialty Clinic:

1. provide guidance for primary caregivers

2. maximize supportive care3. optimize individualized

management5. dissemination of current state of

knowledge

4. clinical trials &5. data collection:

Page 62: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.
Page 63: The Myelodysplastic Syndromes: what they are, what they mean and what are we doing about it Anthony Woods, MD September 30, 2006.

Recommended